Cytarabine

Cytarabine

CAT N°: 16069
Price:

From 74.00 62.90

Cytarabine (ara-C) is a nucleoside analog and prodrug form of the DNA polymerase inhibitor ara-CTP.{48724} It is triphosphorylated to ara-CTP by the successive actions of deoxycytidine kinase, deoxycytidylate kinase, and nucleoside diphosphate kinase.{48725} Ara-C inhibits proliferation of HL-60, ML-1, Raji, and Jurkat human leukemia cell lines with IC50 values of 37, 17, 16, and 72 nM, respectively.{48726} It induces cell cycle arrest at the G0/G1 phase in HL-60 cells when used at concentrations of 2.5 and 15 µM.{48724} ara-C (75 mg/kg per day, i.p.) reduces tumor growth and increases tumor caspase-3 activity in an MOLM-13 mouse xenograft model.{48727} It also increases survival and reduces brain herpesvirus titers in infected rats when administered subcutaneously at doses of 80 and 320 mg/kg.{48728} Formulations containing ara-C have been used in the treatment of acute myeloid leukemia.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 4-amino-1-?-D-arabinofuranosyl-2(1H)-pyrimidinone
  • Correlated keywords
    • inhibitor inhibit cancer antiviral anti virals nucleoside analog DNA polymerase hydroxyl sugar reside triphosphorylated in vivo ara-CTP araCTP ara CTPs ? ? Ac 1075 Ac1075 Ac-1075 alexan ara-cells cells arabinocytosine arabinoside C arabitin aracytidine aracytin aracytine arafcyt CHXs 3311 CHX3311 CHX-3311 citozar cyclocide cylocide N cytarabin cytarabine cytarabinoside cytosar U cytosine arabinoside depocyt depo-cyt cyte erpalfa iretin NSCs 287459 63878 NSC-287459 NSC-63878 NSC287459 NSC63878 spongocytidine tarabine PFS Us U19920 U19920A 19920 19920A U-19920 U-19920A udicil ara-cytosine competitive leukemias ?-D-arabinofuranoside .beta.-D-arabinofuranoside beta-D-arabinofuranoside b-D-arabinofuranoside 1-.beta.-D-Arabinofuranosylcytosine 1-beta-D-Arabinofuranosylcytosine 1-b-D-Arabinofuranosylcytosine
  • Product Overview:
    Cytarabine (ara-C) is a nucleoside analog and prodrug form of the DNA polymerase inhibitor ara-CTP.{48724} It is triphosphorylated to ara-CTP by the successive actions of deoxycytidine kinase, deoxycytidylate kinase, and nucleoside diphosphate kinase.{48725} Ara-C inhibits proliferation of HL-60, ML-1, Raji, and Jurkat human leukemia cell lines with IC50 values of 37, 17, 16, and 72 nM, respectively.{48726} It induces cell cycle arrest at the G0/G1 phase in HL-60 cells when used at concentrations of 2.5 and 15 µM.{48724} ara-C (75 mg/kg per day, i.p.) reduces tumor growth and increases tumor caspase-3 activity in an MOLM-13 mouse xenograft model.{48727} It also increases survival and reduces brain herpesvirus titers in infected rats when administered subcutaneously at doses of 80 and 320 mg/kg.{48728} Formulations containing ara-C have been used in the treatment of acute myeloid leukemia.

We also advise you